Physician profile
Daniel J Lin
NPI 1538158514
$7,384.80
in general payments reported to CMS, 2019-2025
28 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $322 · 2021: $595 · 2022: $1,271 · 2023: $1,637 · 2024: $1,293 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,966.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,313.08 | 2019-2023 | Tepezza, Uplizna |
| Merz Pharmaceuticals, LLC | $977.49 | 2021-2025 | Xeomin |
| Abbvie INC. | $908.26 | 2022-2025 | |
| Amgen INC. | $841.96 | 2024-2025 | Tepezza, Uplizna |
| Argenx US, INC. | $620.22 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $404.76 | 2019-2022 | |
| Alcon Vision LLC | $397.45 | 2019-2025 | Clareon Panoptix Pro, Tryptyr, Eysuvis |
| Ani Pharmaceuticals, INC. | $264.86 | 2023-2025 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $253.65 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Ucb, INC. | $235.44 | 2025 | Rystiggo |
| Sun Pharmaceutical Industries INC. | $204.96 | 2021-2025 | Cequa |
| Janssen Biotech, INC. | $181.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $106.55 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $97.93 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $91.49 | 2023 | Eylea Hd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $73.31 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $71.43 | 2022-2024 | Acthar |
| Dompe US, INC. | $69.29 | 2019-2025 | Oxervate |
| Merz North America, INC. | $65.37 | 2019-2020 | |
| Harrow Eye, LLC | $35.00 | 2025 | Vevye |
| Lombart Brothers, INC. | $30.65 | 2022 | |
| Biotissue Holdings INC. | $30.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $27.01 | 2025 | Ultomiris |
| Smith+Nephew, INC. | $20.74 | 2022 | |
| Aerie Pharmaceuticals, INC. | $16.42 | 2019 | |
| Shire North American Group INC | $15.67 | 2019 | |
| Depuy Synthes Sales INC. | $15.47 | 2022 | |
| Zimmer Biomet Holdings, INC. | $14.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.